Chitosan/alginate crosslinked hydrogels: Preparation, characterization and application for cell growth purposes

Enzyme responsive GAG-based natural-synthetic hybrid hydrogel for tunable growth factor delivery and stem cell differentiation

We describe an enzymatically formed chondroitin sulfate (CS) and poly(ethylene glycol) (PEG) based hybrid hydrogel system, which by tuning the architecture and composition of modular building blocks, allows the application-specific tailoring of growth factor delivery and cellular responses. CS, a negatively charged sulfate-rich glycosaminoglycan of the extracellular matrix (ECM), known for its growth factor binding and stem cell regulatory functions, is used as a starting material for the engineering of this biomimetic materials platform. The functionalization of CS with transglutaminase factor XIII specific substrate sequences is utilized to allow cross-linking of CS with previously described fibrin-mimetic TG-PEG hydrogel precursors. We show that the hydrogel network properties can be tuned by varying the degree of functionalization of CS as well as the ratio and concentrations of PEG and CS precursors. Taking advantage of TG-PEG hydrogel, compatible tagged bio-functional building blocks, including RGD peptides or matrix metalloproteinase sensitive domains, can be incorporated on demand allowing the three-dimensional culture and expansion of human bone marrow mesenchymal stem cells (BM-MSCs). The binding of bone morphogenetic protein-2 (BMP-2) in a CS concentration dependent manner and the BMP-2 release mediated osteogenic differentiation of BM-MSCs indicate the potential of CS-PEG hybrid hydrogels to promote regeneration of bone tissue. Their modular design allows facile incorporation of additional signaling elements, rendering CS-PEG hydrogels a highly flexible platform with potential for multiple biomedical applications.

An Injectable Double-Network Hydrogel for Cell Encapsulation

Further developing on the technique originally intended for the purpose of forming tough hydrogels, we showed in this study that the double-network system can also be used to synthesize an injectable gel. The gel was made up of poly(ethylene glycol) methyl ether methacrylate, sodium alginic acid, and calcium chloride, and two networks, consisting of ionic and covalent networks, were found to co-exist in the gel. Additionally, the rheology studies showed that the mechanical properties of the gel only deteriorated under high strain, demonstrating the robustness of the gel upon injection. The results of a cell cytotoxicity test and a preliminary cell encapsulation study were promising, showing good cell compatibility and thus suggesting that the hydrogels could potentially be used for cell delivery.

Establishment of a controlled insulin delivery system using a glucose-responsive double-layered nanogel

Glucose-responsive glycol chitosan/sodium alginate-poly(l-glutmate-co-N-3-l-glutamylphenylboronic acid) double-layered nanogel is a promising platform for controlled insulin release systems, achieving glucose-triggered insulin release at diabetic glucose levels in vivo.

Local Retention and Combination Effects of Biocompatible Doxorubicin-Loaded and Radioiodine-Labeled Microhydrogels in Cancer Therapy

I-131-labeled chitosan microhydrogels (I-131-CMH) that are retained at an injection site without leaking free I-131 into normal tissue can provide opportunities to improve cancer therapy. This study focuses on the development of doxorubicin-loaded I-131-CMH (Dox-I-131-CMH) for use in radiochemotherapy against cancer. The radiolabeling of I-131-CMH was found to be stable over a period of 2 weeks with no disassociation of free I-131, and Dox showed a sustained release from the CMH. When I-131-CMH were injected into the thigh muscle or tumor tissue, in vivo gamma imaging showed a retention at the injection site with no significant leakage of I-131 into other areas of normal tissue, and after an intrahepatic arterial injection, I-131-CMH were selectively retained in the liver. Dox-I-131-CMH had significant synergistic therapeutic effects of radiation and chemotherapy on mouse breast cancer models. In this regard, Dox-I-131-CMH may be a new alternative agent for cancer therapy.